Literature DB >> 12415607

Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis.

Francesco Zulian1, Giorgia Martini, Fernanda Falcini, Valeria Gerloni, Maria Elisabetta Zannin, Luisa Pinello, Flavio Fantini, Paola Facchin.   

Abstract

OBJECTIVE: To determine whether demographic, clinical, and laboratory variables at onset of arthritis can predict the development and the severity of anterior uveitis (AU) in oligoarticular juvenile idiopathic arthritis (JIA).
METHODS: In a retrospective study, a cohort of 366 patients with oligoarticular onset JIA from 3 pediatric rheumatology centers were evaluated. Patients were classified in 3 groups: severe uveitis (SU) with a mean >/= 2 uveitis relapses/year with complications or need for immunosuppressive therapy; mild uveitis (MU) with a mean </= 1 uveitis relapse/year with no complications; and no uveitis. Variables that were significant with univariate tests or were clinically relevant for each outcome underwent multivariate logistic regression analysis.
RESULTS: There were 316 patients available for analyses: 66 in the SU group, 64 in the MU group, and 186 in the no uveitis group. Multivariate analysis showed the following factors to be significant as predictors of AU onset: low age at onset (OR 0.96), a2-globulin plasma concentration (OR 1.34), and HLA-A19 (OR 2.87), B22 (OR 4.51) and DR9 (OR 2.33), while HLA-DR1 conferred protection (OR 0.13). This model was not good in predicting which patient would develop uveitis (sensitivity 55%, specificity 26%). Time interval between onset of arthritis and the first AU and elevated a2-globulin level in the serum were the best predictors of AU severity (OR 1.62 and 0.85, respectively). When applied prospectively, the model revealed good sensitivity (89.2%), specificity (76.1%), and efficiency (86.3%).
CONCLUSION: Clinical and laboratory variables measurable at onset of arthritis can be used to predict severity of the course of AU in oligoarticular JIA, but not its onset. More accurate prediction can shorten or lengthen the intervals between ophthalmologic evaluations and can change the therapeutic approach undertaken on the basis of expected disease severity.

Entities:  

Mesh:

Year:  2002        PMID: 12415607

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  22 in total

Review 1.  Uveitis in juvenile idiopathic arthritis.

Authors:  Arnd Heiligenhaus; Kirsten Minden; Dirk Föll; Uwe Pleyer
Journal:  Dtsch Arztebl Int       Date:  2015-02-06       Impact factor: 5.594

2.  Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis.

Authors:  Fasika Woreta; Jennifer E Thorne; Douglas A Jabs; Sanjay R Kedhar; James P Dunn
Journal:  Am J Ophthalmol       Date:  2006-12-20       Impact factor: 5.258

Review 3.  The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis.

Authors:  Melissa A Lerman; C Egla Rabinovich
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

4.  HLA Associations in a Cohort of Children With Juvenile Idiopathic Arthritis With and Without Uveitis.

Authors:  Sheila T Angeles-Han; Courtney McCracken; Steven Yeh; Se Ryeong Jang; Kirsten Jenkins; Spencer Cope; John Bohnsack; Aimee Hersh; Susan D Thompson; Sampath Prahalad
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-09       Impact factor: 4.799

Review 5.  Prevention and management of cataracts in children with juvenile idiopathic arthritis-associated uveitis.

Authors:  Sheila Angeles-Han; Steven Yeh
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

6.  High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.

Authors:  H Nida Sen; Grace Levy-Clarke; Lisa J Faia; Zhuqing Li; Steven Yeh; Karyl S Barron; John G Ryan; Keri Hammel; Robert B Nussenblatt
Journal:  Am J Ophthalmol       Date:  2009-08-06       Impact factor: 5.258

Review 7.  [Uveitis in conjunction with rheumatological diseases in childhood].

Authors:  C Sengler; R Keitzer; U Pleyer
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

8.  Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis.

Authors:  Courtney McCracken; Steven Yeh; Kirsten Jenkins; Curtis Travers; Daneka Stryker; Steven Tommasello; Kelly A Rouster-Stevens; Scott R Lambert; Sampath Prahalad; Carolyn Drews-Botsch; Sheila T Angeles-Han
Journal:  Eye (Lond)       Date:  2018-11-28       Impact factor: 3.775

9.  The Association of Race With Childhood Uveitis.

Authors:  Sheila T Angeles-Han; Courtney McCracken; Steven Yeh; Kirsten Jenkins; Daneka Stryker; Curtis Travers; Kelly Rouster-Stevens; Larry B Vogler; Scott R Lambert; Carolyn Drews-Botsch; Sampath Prahalad
Journal:  Am J Ophthalmol       Date:  2015-08-06       Impact factor: 5.258

10.  A reconsideration of anterior chamber flare and its clinical relevance for children with chronic anterior uveitis (an American Ophthalmological Society thesis).

Authors:  Gary N Holland
Journal:  Trans Am Ophthalmol Soc       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.